Anbinder, Ana LiaPrado, Fernanda de Almeida [UNESP]Prado, Marcela de Almeida [UNESP]Balducci, Ivan [UNESP]da Rocha, Rosilene Fernandes [UNESP]2014-05-272014-05-272007-12-01Brazilian Oral Research, v. 21, n. 3, p. 247-252, 2007.1806-83241807-3107http://hdl.handle.net/11449/70091Bisphosphonates are currently used in the treatment of many diseases involving increased bone resorption such as osteoporosis. Statins have been widely used for the treatment of hypercholesterolemia and recent studies have shown that these drugs are also capable of stimulating bone formation. The purpose of this study was to evaluate thel influence of an estrogen deficient state and the effects of simvastatin and sodium alendronate therapies on alveolar bone in female rats. Fifty-four rats were either ovariectomized (OVX) or sham operated. A month later, the animals began to receive a daily dose of simvastatin (SIN - 25 mg/kg), sodium alendronate (ALN - 2 mg/kg) or water (control) orally. Thirty-five days after the beginning of the treatment, the rats were sacrificed and their left hemimandibles were removed and radiographed using digital X-ray equipment. The alveolar radiographic density under the first molar was determined with gray-level scaling and the values were submitted to analysis of variance (α = 5%). Ovariectomized rats gained more weight (mean ± standard deviation: 20.06 ± 6.68%) than did the sham operated animals (12.13 ± 5.63%). Alveolar radiographic density values, expressed as gray levels, were lowest in the OVX-water group (183.49 ± 6.47), and differed significantly from those observed for the groups receiving alendronate (sham-ALN: 193.85 ± 3.81; OVX-ALN: 196.06 ± 5.11) and from those of the sham-water group (193.66 ± 4.36). Other comparisons between groups did not show significant differences. It was concluded that the ovariectomy reduced alveolar bone density and that alendronate was efficient for the treatment of this condition.247-252engAlendronateModels, animalOsteoporosisOvariectomySimvastatinalendronic acidantilipemic agentbone density conservation agentestrogenhydroxymethylglutaryl coenzyme A reductase inhibitorsimvastatinanalysis of varianceanimalbone densitydisease modeldrug effectdrug screeningfemalehypercholesterolemiajawmandibleosteolysisosteoporosisovariectomyrandomizationratWistar ratAlveolar Bone LossAlveolar ProcessAnalysis of VarianceAnimalsAntilipemic AgentsBone DensityBone Density Conservation AgentsDisease Models, AnimalDrug Evaluation, PreclinicalEstrogensFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMandibleRandom AllocationRatsRats, WistarArtigo10.1590/S1806-83242007000300010S1806-83242007000300010Acesso aberto2-s2.0-390491494342-s2.0-39049149434.pdf609796794300827301903652345160270000-0003-3930-4274